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ABSTRACT
Introduction: The emergence of antibiotic-resistant
bacteria has driven renewed interest in older
antibacterials, including colistin. Previous studies have
shown that colistin is less effective and more toxic
than modern antibiotics. In vitro synergy studies and
clinical observational studies suggest a benefit of
combining colistin with a carbapenem. A randomised
controlled study is necessary for clarification.
Methods and analysis: This is a multicentre,
investigator-initiated, open-label, randomised controlled
superiority 1:1 study comparing colistin monotherapy
with colistin–meropenem combination therapy for
infections caused by carbapenem-resistant Gram-
negative bacteria. The study is being conducted in 6
centres in 3 countries (Italy, Greece and Israel). We
include patients with hospital-associated and ventilator-
associated pneumonia, bloodstream infections and
urosepsis. The primary outcome is treatment success
at day 14, defined as survival, haemodynamic stability,
stable or improved respiratory status for patients with
pneumonia, microbiological cure for patients with
bacteraemia and stability or improvement of the
Sequential Organ Failure Assessment (SOFA) score.
Secondary outcomes include 14-day and 28-day
mortality as well as other clinical end points and safety
outcomes. A sample size of 360 patients was
calculated on the basis of an absolute improvement in
clinical success of 15% with combination therapy.
Outcomes will be assessed by intention to treat. Serum
colistin samples are obtained from all patients to
obtain population pharmacokinetic models.
Microbiological sampling includes weekly surveillance
samples with analysis of resistance mechanisms and
synergy. An observational trial is evaluating patients
who met eligibility requirements but were not
randomised in order to assess generalisability of
findings.
Ethics and dissemination: The study was approved
by ethics committees at each centre and informed
consent will be obtained for all patients. The trial is
being performed under the auspices of an independent
data and safety monitoring committee and is included
in a broad dissemination strategy regarding revival of
old antibiotics.
Trial registration number: NCT01732250 and 2012-
004819-31; Pre-results.
INTRODUCTION
Background and rationale
Colistin, discovered in 1947, has resurged in
the past decade for the treatment of
multidrug-resistant Gram-negative bacteria
(GNB). As a polymyxin, it acts both by dis-
rupting the cell membrane and by binding
lipid polysaccharide and blocking the effects
of endotoxin.1 2 Polymyxins are bactericidal
by inducing rapid cell death mediated
through hydroxyl radical production.3
Observational studies suggested higher mor-
tality among patients treated with colistin or
polymyxin B compared with patients given
other antibiotics, mostly β-lactams.4 5 Despite
the fact that most of these studies were
limited by the probable underdosing of
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colistin, the pooled rates of nephrotoxicity were higher
with colistin compared with other antibiotics.4 Rates of
nephrotoxicity in recent studies designed to assess this
outcome have ranged from 6–14% to 32–55%, with
much of the difference due to different deﬁnitions of
renal failure.6–15 The daily dose12 15 and the total cumu-
lative dose10 11 16 have been associated with increased
risk of nephrotoxicity. Additionally, colistin is associated
with neurological toxicity that is more difﬁcult to
appreciate in critically ill patients.17
Studies currently focus on improving the efﬁcacy and
safety proﬁle of colistin, combination therapy being one
commonly adopted strategy. Ideally, a combination
regimen should improve clinical success via improved
reduction of the bacterial load, more rapid killing,
killing or inhibition at lower drug concentrations, thus
avoiding toxicity and minimising the risk of resistance
selection. Carbapenems are commonly added to colistin
in clinical practice for the treatment of infections due to
carbapenem-resistant GNB (CR GNB). Several recent
observational studies concluded that combination thera-
pies including a carbapenem have a signiﬁcant and
important advantage over colistin monotherapy.18–23
These studies have been highly inﬂuential on clinical
practice worldwide, leading to the view that colistin
should not be used as monotherapy. The limitations of
these studies include indication bias inherent to observa-
tional studies comparing treatment regimens, moderate
to very small sample sizes, inclusion of multiple different
regimens in the combination arm and inclusion of
carbapenemase-producing carbapenem-susceptible bac-
teria together with CR bacteria.24
To formally appraise the potential beneﬁt of poly-
myxin–carbapenem combination therapy, we conducted
a systematic review and meta-analysis of their in vitro
interactions.25 We found that in time-kill studies, carba-
penem–polymyxin combination therapy showed synergy
rates of 77% (95% CI 64% to 87%) for Acinetobacter bau-
mannii, 44% (95% CI 23% to 51%) for Klebsiella pneumo-
niae and 50% (95% CI 30% to 69%) for Pseudomonas
aeruginosa with low antagonism rates for all. For A. bau-
mannii, meropenem was more synergistic than imipe-
nem, whereas for P. aeruginosa the opposite was true. In
studies on single isolates, the use of combination
therapy led to less resistance development in vitro.
Higher synergy rates, observed more frequently with A.
baumannii than with K. pneumonia or P. aeruginosa
strains, could have been related to lower minimal inhibi-
tory concentration (MICs) of A. baumannii to carbape-
nems in general. Differences between carbapenems
were less clear and depended on bacteria type. The sys-
tematic review supported a biological rationale for a clin-
ical trial, along with the selection of meropenem as the
carbapenem of choice in order to maximise the advan-
tage to combination therapy as A. baumannii is the domi-
nant bacterium at the trial sites.
Learning from in vitro studies on clinical effects is dif-
ﬁcult because the bacterial inocula differ, drug levels
may be affected by practical constraints of antibiotic
administration and clinical effects are confounded by
underlying conditions and adverse effects. Previous ana-
lyses have shown that despite strong in vitro proof of
synergy and prevention of resistance selection for
β-lactams and aminoglycosides, randomised controlled
trials (RCTs) did not show a clinical beneﬁt for the same
combinations compared with β-lactams alone in the
treatment of sepsis.26–28 Furthermore, the possibility of
further resistance selection due to widespread carbape-
nem usage following adoption of combination therapy
as a policy, increased toxicity and antagonistic interac-
tions between antibiotics may render combination
therapy worse than monotherapy and not merely non-
inferior. Thus, despite in vitro data supporting synergy
between carbapenems and colistin, proof of improved
clinical outcome is essential.
Objectives
Our study was born from the need to examine in an
unbiased way whether combination therapy offers an
advantage. To this end, a prospectively designed RCT
methodology was chosen to enable strict deﬁnitions of
the treatment regimens, optimal antibiotic dosing and
schedule deﬁnitions and treatment assignment unre-
lated to infection or patient characteristics.
The primary objective of the trial is to show superiority
of colistin-meropenem combination therapy to colistin
monotherapy in the treatment of patients infected with
CR GNB. A secondary objective is to obtain improved
population pharmacokinetic models (PPMs) for colistin.
METHODS AND ANALYSIS
Design
Multicentre, open-label, 1:1 superiority randomised con-
trolled trial.
Setting
The study is currently ongoing at Laikon and Attikon
Hospitals in Athens, Greece; Tel Aviv Medical Center
(Tel Aviv), Rabin Medical Center, Beilinson Hospital
(Petah-Tikva) and Rambam Health Care Center
(Haifa), Israel; and Monaldi Hospital, Naples, Italy.
Recruitment began in October 2013 and is planned to
continue until November 2016.
Eligibility criteria
Inclusion criteria
We include adult inpatients ≥18 years with ventilator-
associated pneumonia (VAP), hospital-acquired pneumo-
nia (HAP), urosepsis or bloodstream infections of any
source, as deﬁned in table 1, caused by carbapenem
non-susceptible and colistin-susceptible GNB, including
Acinetobacter spp., P. aeruginosa or any Enterobacteriaceae
(including but not limited to K. pneumoniae, Escherichia
coli and Enterobacter spp.). Patient recruitment occurs
only after microbiological documentation, susceptibility
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testing and signed informed consent. Carbapenem non-
susceptibility is deﬁned using the EUCAST breakpoint
of minimal inhibitory concentration (MIC) >2 mg/L
and colistin susceptibility as MIC ≤2 mg/L for
Acinetobacter spp. and Enterobacteriaceae and ≤4 mg/L
for Pseudomonas spp. We include patients with infections
caused by bacteria susceptible to sulbactam, tetracy-
clines, tigecycline, cotrimoxazole or aminoglycosides as
we consider that these are not established treatments for
severe Gram-negative infections and nor has their super-
iority to colistin been established. We permit the inclu-
sion of patients with polymicrobial infections where all
Gram-negative isolates are carbapenem non-susceptible,
or mixed with Gram-positive bacteria or anaerobes (see
permitted additional antibiotics below). Inclusion is
based on the testing performed in individual study hos-
pitals after mapping the acceptability of the methods
used in participating hospitals. Isolate identiﬁcation and
carbapenem MICs are conﬁrmed in a central laboratory.
Exclusion criteria
We exclude patients treated with colistin for more than
96 h prior to randomisation, but encourage all efforts to
recruit patients as soon as possible after identiﬁcation.
The relatively long time period permitted for effective
treatment prior to study enrolment was deﬁned to allow
maximal patient inclusion in hospitals using colistin
empirically and for patients identiﬁed during weekends
and holidays. We exclude infections when the CR isolate
is susceptible to quinolones or any β-lactam. Similarly,
we exclude patients with polymicrobial infections where
one or more of the clinically signiﬁcant GNB are suscepti-
ble to any β-lactam as we do not consider it appropriate
to treat a β-lactam-susceptible Gram-negative bacterium
Table 1 Inclusion criteria for infections
Type of
infection Definition
BSI Growth of the relevant bacteria in one or more blood culture bottles accompanied by the SIRS within 48 h
of blood culture taken time. BSIs can be either primary or secondary to any other source of infection.
VAP or HAP Pneumonia fulfilling CDC/NHSN surveillance definition of healthcare-associated infection for pneumonia
with specific laboratory findings (PNU2) with modifications to the laboratory criteria.29 Ventilator-associated
pneumonia will be defined in persons who had a device to assist or control respiration continuously through
a tracheostomy or by endotracheal intubation within the 48 h period before the onset of infection. BAL will
not be performed routinely for the purposes of the trial. The specific criteria required for diagnosis of
pneumonia will be all of the following:
1. Chest radiograph with new or progressive and persistent infiltrate, consolidation or cavitation;
2. At least 1 of the following signs of sepsis: fever >38°C with no other recognised cause; leucopaenia
<4000 WCC/mm3 or leucocytosis >12 000 WCC/mm3; for adults aged >70 years, altered mental status
with no other recognised cause;
3. At least 1 of the following respiratory signs/symptoms: new onset of purulent sputum or change in
character of sputum or increased respiratory secretions or increased suctioning requirements; new
onset or worsening cough or dyspnoea or tachypnoea >25 breaths per minute; rales or bronchial breath
sounds; worsening gas exchange, including O2 desaturations, PaO2/FiO2 <240 or increased oxygen
requirements;
4. Laboratory criterion: growth of the relevant bacteria in culture of sputum, tracheal aspirate, BAL or
protected specimen brushing. For any lower respiratory secretion other than BAL or PSB, the
respiratory sample has to contain >25 neutrophils and <10 squamous epithelial cells per low power
field, identified by Gram stain.
Probable VAP Pneumonia fulfilling the CDC/NHSN 2013 revised surveillance definition, omitting the criterion of
antimicrobial treatment before randomisation and modifying the microbiological criteria:30
1. Mechanical ventilation for ≥3 calendar days;
2. Worsening oxygenation, following ≥2 calendar days of stable or decreasing FiO2 or PEEP, presenting as:
▸ Minimum daily FiO2 values increase ≥0.20 (20 points) over baseline and remain at or above that
increased level for ≥2 calendar days OR
▸ Minimum daily PEEP values increase ≥3 cm H2O over baseline and remain at or above that
increased level for ≥2 calendar days.
3. Temperature >38°C or <36°C, OR white cell count ≥12 000 cells/mm3 or ≤4000 cells/mm3;
4. Purulent respiratory secretions AND positive respiratory culture; OR positive culture of pleural fluid. For
any lower respiratory secretion other than BAL or PSB, the respiratory sample has to contain >25
neutrophils and <10 squamous epithelial cells per low power field, identified by Gram stain.
Urosepsis Positive urine culture with relevant bacteria ≥105 CFU/mL with pyuria, accompanied by the SIRS within
48 h of taken time and no other explanation for SIRS
BAL, bronchoalveolar lavage; BSI, bloodstream infection; CDC/NHSN, Centers for Disease Control and Prevention/ National Healthcare
Safety Network; FiO2, fractional inspired oxygen; HAP, healthcare-associated pneumonia; PaO2, arterial oxygen tension; PEEP, positive end-
expiratory pressure; PSB, protected specimen brush; SIRS, systemic inflammatory response syndrome; VAP, ventilator-associated
pneumonia; WCC, white cell count.
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with colistin monotherapy given the data available from
observational studies on colistin’s inferiority to β-lactams.
In addition, we exclude patients in whom informed
consent cannot be obtained, those who were previously
enrolled in the trial, pregnant women and those with a
known allergy to colistin or carbapenems. Pregnancy
testing is not performed routinely in fertile women not
known to be pregnant for the purposes of the trial.
Originally, we excluded all patients with seizures because
of the fear of inducing seizures with high-dose merope-
nem. Subsequently, we introduced an amendment
to exclude only those who have a history of prior
carbapenem-induced seizures and patients with epilepsy
requiring chronic antiepileptic treatment unless treated
previously with a carbapenem for more than 48 h without
experiencing a seizure. The amendment was supported
by clinical practice in the study centres when treating
other patients at risk for carbapenem-induced seizures.
Interventions
At the time of the protocol design, pharmacokinetic
(PK) studies demonstrated that it takes about 36–48 h
for colistin to reach therapeutic concentrations in
plasma (≥2 mg/L), using classical dosing in patients
with normal renal function.31 32 Thus, a loading dose
equal to the approximate total daily dose was sug-
gested.33 Furthermore, these studies demonstrated that
once or twice daily dosing is probably sufﬁcient. We tai-
lored the colistin administration regimen in the trial
according to these data.34
Colistin arm
Patients receive a loading dose of 9 MIU, regardless of
renal function. For patients with normal renal function
(CrCl ≥50 mL/min), the loading dose is followed by
4.5 MIU q12 h32 35 beginning 12 h after the loading
dose. Colistin is administered as a 30 min intravenous
infusion. Patients treated with colistin before randomisa-
tion are given a loading dose if treated for <48 h without
a loading dose at the start of treatment. Patients who
previously received a loading dose or who have been
treated for 48 h or more continue colistin without a
loading dose, using the trial schedule. Maintenance
dose adjustment for patients with renal failure is based
on the study by Garonzik et al31 aiming to achieve a colis-
tin steady state average level of 2–2.5 mg/L (table 2). No
dosage adjustments are performed for hepatic
insufﬁciency.
Colistin+meropenem arm
Colistin is administered as above and combined with
intravenous meropenem 2 g q8 h for patients with
normal renal function (CrCl >50 mL/min). Meropenem
is administered as a prolonged infusion over 3 h. For
patients with impaired renal function, dosing is adjusted
(table 2) without a change in the infusion time.36 No
dosage adjustments are performed for hepatic
insufﬁciency.
For both treatment arms, the recommended duration
of antibiotic treatment is at least 10 days for all listed
indications. If infectious complications mandate longer
treatment, duration is prolonged as appropriate. We
permit the concomitant administration of the following
antibiotics for polymicrobial infections: vancomycin, oxa-
cillin derivatives, cefazolin, ampicillin, penicillin or
metronidazole. We do not permit the routine addition
of rifampin, tigecycline, minocycline, aminoglycosides or
colistin inhalations.
Outcomes
The primary outcome is treatment success measured at
14 days from randomisation. Success is deﬁned as a compo-
site of survival; haemodynamic stability; stable or improved
respiratory status for patients with pneumonia; microbiolo-
gical cure for patients with bacteraemia; and stability or
improvement of the Sequential Organ Failure Assessment
(SOFA) score (table 3). Treatment failure is deﬁned as the
failure to meet any of the composite criteria on day 14.
The outcome was deﬁned by consensus of the investigators
addressing clinically relevant outcome measures among
critically ill patients and after reviewing published outcome
deﬁnitions for HAP/VAP37 and Food and Drug
Administration (FDA) and European Medicines Agency
(EMA) guidance on the design of clinical trials of antibac-
terials.38 Secondary outcomes include 14-day and 28-day
all-cause mortality; clinical success without modiﬁcation of
Table 2 Drug dosing schedule
Renal function Colistin maintenance dose* Meropenem dosing
CrCl ≥50 mL/min† 4.5 MIU q12 h 2 g q8 h
CrCl <50 mL/min, without renal
replacement therapy
Total daily dose in MIU=(2×(1.5×CrCl
+30))/30
CrCl 26–50 mL/min: 2 g q12 hCrCl
10–25 mL/min: 1 g q12 h
Continuous renal replacement
therapy
Fixed dose of 6 MIU q12 h 1 g q12 h
Intermittent haemodialysis 1 MIU q12 h, with a 1 MIU supplemental
dose after dialysis
1 g q24 h with a supplemental dose given
after dialysis
*All patients receive a loading dose of 9 MIU regardless of renal function. Adjustment refers only to the maintenance dose started 12 h after
the loading dose.
†CrCl should be expressed in mL/min/1.73 m2, using the modification of diet in renal disease (MDRD) formula, Cockcroft and Gault equation
or other means.
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the assigned antibiotic regimen; time to defervescence;
time to weaning from mechanical ventilation in VAP; time
to hospital discharge; change in functional capacity; micro-
biological failure; superinfections; colonisation by CR or
colistin-resistant bacteria; Clostridium difﬁcile infection
(CDI); renal failure; seizures and other adverse events.
Outcome deﬁnitions are provided in table 3.
PK assessment
Two blood samples for colistin levels are obtained from all
patients included in the trial. The ﬁrst sample is obtained
15 min after the end of the loading dose (45 min from its
start). The second sample is obtained 10 h after the
second colistin dose (22 h from the start of the loading
dose). For patients treated with colistin before randomisa-
tion, samples are taken 15 min following the ﬁrst
postrandomisation dose and 2 h prior to the third. This
sparse sampling strategy was deemed to provide the
optimal information on individual colistin exposure based
on practical constraints, previous modelling of colistin
PK32 35 and the optimal design methodology.40
Meropenem concentrations are determined using the
same samples for those patients receiving combination
therapy. Plasma samples are frozen immediately at the
study centres and sent for analysis of colistin levels at a
central laboratory in Uppsala University, Sweden, and
from there to Erasmus MC for assessment of meropenem
concentrations where applicable.
Participant timeline
All patients are followed up to 28 days following enrolment
in the trial. For hospitalised patients, follow-up is
Table 3 Outcomes
Outcome Definition
Clinical success (primary
outcome)
Composite of:
▸ Patient alive
▸ Systolic blood pressure >90 mm Hg without need for vasopressor support
▸ Stable or improved SOFA score, defined as:
– For baseline SOFA ≥3: a decrease of at least 30%
– For baseline SOFA <3: stable or decreased SOFA score
▸ For patients with HAP/VAP, PaO2/FiO2 ratio stable or improved
▸ For patients with bacteraemia, no growth of the initial isolate in blood cultures taken on
day 14 if patient still febrile
14-day all-cause mortality
28-day all-cause mortality
Clinical success without
modification
Clinical success, as defined above, but any modification to the antibiotic treatment not
permitted by protocol will also be considered as a failure. This will include any change or
addition of antibiotics not permitted by the study protocol during the first 10 days after
randomisation. Early discontinuation of antibiotic treatment will not be considered as a
failure.
Time to defervescence Time to reach a temperature of <38°C with no recurrence for 3 days
Time to weaning from mechanical
ventilation
Days from randomisation to weaning for patients with VAP weaned alive
Time to hospital discharge Days to hospital discharge among patients discharged alive
Change in functional capacity Assessed from baseline status before infection onset to discharge from hospital
Function capacity will be classified into 3 grades:
1. Independent
2. Need for assistance for activities of daily living
3. Bedridden
Microbiological failure Isolation of the initial isolate (phenotypically identical) in a clinical sample (blood or other)
7 days or more after start of treatment or its identification in respiratory samples (see Data
collection and microbiological sampling and table 4 below)
Superinfection New clinically or microbiologically documented infections by CDC criteria within 28 days,
any and specifically those caused by newly acquired carbapenem-resistant or
colistin-resistant Gram-negative bacteria
Resistant colonisation Colonisation by phenotypically newly acquired carbapenem-resistant or colistin-resistant
Gram-negative bacteria. Assessed by rectal surveillance (see Data collection and
microbiological sampling and table 4 below)
CDI Diarrhoea with a positive Clostridium difficile toxin test
Renal failure Renal failure using the RIFLE criteria39 at days 14 and 28 relative to the day of
randomisation
Seizures Seizures or other neurological adverse events including critical illness neuropathy
Other adverse events Requiring treatment discontinuation
CDC, Centers for Disease Control and Prevention; CDI, Clostridium difficile infection; FiO2, fractional inspired oxygen; HAP, hospital-acquired
pneumonia; PaO2, arterial oxygen tension; SOFA, Sequential Organ Failure Assessment; VAP, ventilator-associated pneumonia.
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performed on a regular basis through study visits (table 4)
and daily through patients’ records. In the rare instances
in which patients are discharged before day 28, follow-up
is completed via the appropriate healthcare system
databases.
Sample size
The expected mortality in our trial cohort is approxi-
mately 30%, based on previous studies.41–43 A reanalysis
of a cohort study by the researchers indicated a 55%
treatment success rate using our primary composite
outcome deﬁnitions.5 To show an improvement in treat-
ment success (primary outcome) from 55% with colistin
alone to 70% with combination therapy with a 1:1 ran-
domisation ratio, a sample of 324 patients (162 per
group) was deemed necessary (uncorrected χ2 test,
α=0.05, power=0.8, PS Power and Sample Size
Calculations). Assuming a non-evaluability rate of about
10%, we plan to recruit 360 patients.
Patient identification, randomisation and blinding
Potential patients are identiﬁed through daily or twice-
daily reports on CR isolates from blood, urine and
sputum samples from the microbiology laboratory. After
determining whether patients fulﬁl inclusion and exclu-
sion criteria, randomisation is performed by investigators
from the respective centres. Central randomisation is
performed using a custom-built web application, using
randomised permuted blocks of varying length, stratiﬁed
by centre. The ﬁrst block in each strata begins at a
random position.44 Each randomisation attempt requires
entry of a matching unique ID from the Epi-Info case
report form (CRF) generated when entering patients’
eligibility (see below, data collection), and each rando-
misation attempt is logged. No blinding is used after ran-
domisation. Outcome adjudication will be performed
centrally blinded to the assigned intervention using the
clinical data collected by individual centre investigators.
Data collection and microbiological sampling
We designed a CRF using the Epi-Info free software
package (http://wwwn.cdc.gov/epiinfo/). A database is
kept at each site, from which anonymised data are
exported periodically and sent to the primary investiga-
tor. See box 1 for a list of the data collected and partici-
pant timeline above. For assessment of microbiological
response, synergy and resistance development, we obtain
(in addition to the index culture deﬁned for trial inclu-
sion) a sample from the primary source of isolation of
the CR GNB on day 7 (sputum for patients with HAP/
VAP and urine for patients with urosepsis) and rectal
swabs for CR GNBs isolation on days 1, 7, 14 and 28;
samples are collected from all patients. Blood cultures
are repeated every 48 h as long as the patient is febrile.
Treating physicians will be permitted to obtain other
samples at their own discretion. The index isolate as well
as all phenotypically identical repeat isolates are kept for
Box 1 Data collected for randomised controlled trial
patients
▸ Patient demographics
▸ Background conditions, including the revised Charlson comor-
bidity index45 and McCabe score
▸ Source of infection and diagnostic criteria for ventilator-
associated pneumonia and hospital-acquired pneumonia
including type of respiratory specimen used for patient
classification
▸ Devices present at infection onset and risk factors for
multidrug-resistant colonisation and infection
▸ Antibiotic treatment prior to onset of the infectious episode,
empirical antibiotic treatment and all antibiotics used from ran-
domisation until day 28. We will document colistin administra-
tion times.
▸ Concomitant nephrotoxic agents: aminoglycosides, intrave-
nous contrast material, cyclosporine
▸ Therapeutic procedures throughout the infectious episode
(surgery, catheter extraction, etc)
▸ Use of colistin inhalation therapy
▸ Sequential Organ Failure Assessment (SOFA) score
▸ All outcomes as defined
Table 4 Participant timeline for RCT
Day
Enrolment and
randomisation
Background
and clinical
information
Colistin
levels
Clinical
follow-up
Outcome
data
Rectal
surveillance
swabs
Blood
cultures
if febrile
Other
microbiological
sampling*
1 X X X X X X
2 X X X
5 X X
7 X X X X X
9 X
10 X
14 X X X X
21 X
28 X X X
*Index culture on day 1 (randomisation); Sputum culture for patients with HAP/VAP and urine culture for patients with urosepsis on day 7.
HAP, hospital-acquired pneumonia; RCT, randomised controlled trial; VAP, ventilator-associated pneumonia.
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further analyses. Samples are frozen and analysed cen-
trally at Tel-Aviv Medical Center in Israel.
Concomitant observational study
Previous studies have found that the patients included in
RCTs of antibiotics differ signiﬁcantly from patients
encountered in clinical practice, particularly among the
critically ill.46 47 This difference threatens the external
validity and therefore the generalisability of the ﬁndings
in these trials. In order to examine the external validity
of the present trial and to provide an observational com-
parison between the trial treatment regimens in the
overall cohort, we are collecting all clinical data and
treatment regimens from patients not included in the
RCT for the reasons detailed in box 2 but otherwise ful-
ﬁlling clinical and microbiological inclusion criteria.
Treatment in this arm is based on the attending physi-
cians’ decisions. Clinical and microbiological samples
for these patients are collected only for routine purposes
and are neither kept nor analysed as for the main trial.
Data are kept anonymously. Informed consent for data
collection is not required, as no intervention is planned.
Statistical analysis
The primary analysis will be by intention to treat for all
randomised patients by their treatment assignment. A
secondary analysis per protocol will be deﬁned for
patients surviving at least 48 h and receiving at least
5 days of the assigned antibiotic regimen (type and
dose) or until death if death occurs between days 3 and
5, without concomitant antibiotics active against the CR
GNB. Predeﬁned subgroup analyses for the primary and
mortality outcomes include:
▸ Patients who did not receive covering antibiotic treat-
ment in the ﬁrst 48 h after culture taken date
(patients receiving inappropriate empirical antibiotic
treatment)
▸ Patients with VAP/HAP or bacteraemia (excluding
probable VAP and urosepsis)
▸ Patients in whom the infecting bacteria has an MIC
to meropenem <16 mg/L.
Baseline characteristics and outcomes of the study
groups will be compared. Signiﬁcance will be set at
p<0.05 and all tests will be two sided. Time-to-event out-
comes will be assessed using survival analysis. We will
conduct a multivariable analysis of the randomised
cohort and the randomised+observational cohorts (see
below) to examine the independent effect of the study
regimen on 28-day mortality. A PK/pharmacodynamic
(PD) analysis is also planned, using the same outcomes,
but with PK/PD parameter estimates of individual
patients as exploratory variables.
Data and safety monitoring
This trial is part of the larger ‘Preserving old antibiotics
for the future: assessment of clinical efﬁcacy by a phar-
macokinetic/pharmacodynamic approach to optimize
effectiveness and reduce resistance for off-patent antibio-
tics (AIDA)’ project, which is designed to assess the efﬁ-
cacy and safety of old, revived antibiotics in the
treatment of infections with antibiotic-resistant bacteria.
As such, the trial is being performed under the auspices
of the data and safety monitoring committee (DSMC) of
the AIDA project which is independent of the organisers
of the study and the AIDA project. The DSMC has full
access to the trial data for review. In addition, there will
be three yearly evaluations over the course of the trial at
which a summary of trial procedures to date will be
presented.
Both antibiotics studies have long been in use, mero-
penem’s adverse event proﬁle is known and we do not
expect speciﬁc adverse events related to the interaction
between colistin and meropenem. The main concern
with combination therapy relative to colistin monother-
apy is resistance development and Clostridium difﬁcile
infection. We will monitor both, addressing resistance
development through the search for and documentation
of colonisation and clinical infections with new CR
GNBs and any colistin-resistant GNBs.
No interim analyses are planned. In our trial, the risks
that the trial arm (combination therapy) is associated
with signiﬁcantly better or worse outcomes than the
control arm (monotherapy) such that an interim analy-
sis would lead to early stopping were assessed as low.
ETHICS AND DISSEMINATION
The study was approved by the ethics committees at
each participating centre and informed consent is
obtained for all patients. In Italy and Greece, a relative is
an acceptable surrogate for patients unable to provide
informed consent. In Israel, consent from a legal guar-
dian or an independent physician (providing direct
patient care but not participating in the study) is accep-
table, the latter since the study was approved as ‘emer-
gency research’.
The trial was registered with the National Institutes of
Health (NIH) trial registry (NCT01732250; registered
on 19 November 2012) and European Union Drug
Regulating Authorities Clinical Trials (EudraCT) registry
(2013-005583-25; registered on 8 July 2013) before the
start of the trial.
The study investigators pioneered a coordinated initia-
tive to ‘redevelop’ old, now resurgent antibiotics that
Box 2 Eligibility criteria for observational study
▸ Unable to provide informed consent or otherwise no informed
consent
▸ Identified later than 96 h after start of treatment
▸ Second and subsequent episodes of infection for patients
included in the randomised controlled trial. A separate episode
of infection will be defined as an infection occurring at least
28 days after the index episode of infection and separated by
at least 7 days of antibiotics.
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have never been analysed in a structured process for
drug assessment and regulatory approval meeting
current scientiﬁc standards. We organised an interna-
tional conference to raise broad awareness and
addressed the need for a structured process to ﬁll the
knowledge gaps for old revived antibiotics.48 A series of
publications highlighted a range of topics regarding old
antibiotics.49–54 Similarly, study investigators actively par-
ticipated in the ﬁrst and second international polymyxin
conferences where the study protocol and progress were
discussed.55 A range of dissemination activities are
planned or ongoing, including educational courses dedi-
cated to advances in optimising the use of colistin and
other revived antibiotics as well as presentations and
educational workshops at international conferences.
Ongoing PK analyses, an integral part of the colistin
study, are being presented at international conferences.
We will publish the ﬁnal report of the study.
DISCUSSION
This trial is part of the larger AIDA project (http://www.
aida-project.eu) which has been designed to analyse the
clinical effectiveness and optimal dosing of older antibio-
tics, including colistin, fosfomycin, nitrofurantoin, minocy-
cline and rifampicin (see http://www.aida-project.eu).
Within this wider framework, two further RCTs are under-
way as well as a series of linked microbiological and PK/
PD studies. The linked microbiological study of our trial
will examine the effect of treatment regimen on density of
resistant strains and the co-carriage of various CR strains.
Co-carried resistant strains belonging to different species
and newly acquired resistant strains will be further studied
for mechanisms of resistance. An analysis is planned to
examine correlations between carbapenem MICs, colistin
MICs, molecular typing, mechanisms of resistance and
synergy studies with treatment outcomes including clinical
success, microbiological failure and emergence of resis-
tance. PK studies completed after the launch of our trial
challenge the need for a loading dose.56 We hope that
new PK data generated on a large sample of patients
during the course of this trial will help to provide a deﬁni-
tive answer. In the linked PK/PD study, we plan to improve
PPMs for colistin, predict exposures in individual patients
using PPM and in the population by Monte Carlo simula-
tions, correlate exposures with outcomes (efﬁcacy and
emergence of drug resistance) for colistin monotherapy
versus combination therapy and determine cut-offs of PD
indices using Classiﬁcation and Regression Tree (CART)
analysis and logistic regression analysis, determine target
exposures for each drug and combinations in preclinical
models and suggest clinical breakpoints.
A concurrent NIH-funded RCT is being conducted in
the USA, assessing similar interventions and using compar-
able microbiological methods (NCT01597973). An agree-
ment has been reached between the NIH trial and this
trial’s’ primary investigators to examine possible collabora-
tion. We are trying to ensure comparability between this
trial and the NIH trial, particularly with respect to the out-
comes assessed to allow for comparison and compilation
of results after analysis of this trial. We will pool results
using methods of individual patient-level meta-analysis.
Antibiotic approval trials are predominantly indication-
based, focusing on a single indication such as VAP,
complicated urinary tract infection (UTI), etc. Our trial is
pathogen-based, comprising a spectrum of infections that
are caused by CR GNB and for which colistin is utilised.
Though our trial design is focused on practicability and on
mirroring clinical practice, it may offer valuable experi-
ence for future pathogen-directed designs in critically ill
patients that need to meet regulatory requirements based
on EMA’s 2013 guideline. A problem may arise in trials
focusing on pathogens if treatment effects differ signiﬁ-
cantly for different sites of infection. PK models of differ-
ent infection sites as well as pooling results with the NIH
trial to allow for subgroup analyses by types of infections
may support the validity of the results of a pathogen-
focused trial. Outcomes deﬁned for indication-based trials
were inadequate for our trial. We sought an outcome that
would reﬂect a clinically signiﬁcant beneﬁt for critically ill
patients, recognising that survival is a key outcome in this
population. The proximity to randomisation (14-day
outcome as currently recommended for severe infections)
increases the chances that mortality is related to the infec-
tion and its treatment.
During the process of obtaining approval for this trial
at the participating sites, it became clear that numerous
differences exist between the regulatory requirements of
the countries involved. Among these is the approach to
informed consent in incapacitated patients, as were
nearly all patients included in our trial. The Declaration
of Helsinki states “For a potential research subject who is
incapable of giving informed consent, the physician
must seek informed consent from the legally authorised
representative”.57 In most countries involved in the
present study, a relative is an acceptable surrogate which
renders clinical trials among incompetent patients feasi-
ble. At the Israeli sites, on the other hand, the represen-
tative must be someone with a court-appointed power of
attorney over the patient’s person. The European coun-
tries participating in the trial had no mechanisms in
place to provide for patients who cannot provide
consent and for whom a representative is lacking. In
Israel, the study was approved under the label of ‘emer-
gency research’ allowing an independent physician to
provide consent of incapacitated patients. Such an
approval is granted for trials in which (1) the patient is
in an immediate life-threatening condition, existing
treatments are unsatisfactory, it is important to deﬁne
optimal treatment for the condition and the study could
not have been performed had informed consent been
required; (2) the patient’s life-threatening condition
requires treatment and preclinical studies point in
favour of the intervention assessed; (3) it is impossible
to obtain informed consent from the patient because of
the acute condition and treatment has to be provided in
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a time window that does not allow assignation of a legal
guardian. The researcher is obliged to request informed
consent from the patient once the acute condition is
reversed and it is mandated that an independent data
monitoring and safety committee and the ethics commit-
tee follow the trial.
The implications of the differences between countries are
ethical, methodological and practical. Certainly, it is desir-
able that the patient’s medical surrogate has the patient’s
best interests at heart as well as shares common values with
the patient regarding issues related to medical decision-
making. While the precise genealogical relationship
between two individuals is not a guarantor of these ideals, a
system needs to be in place to ensure them. Although the
law could automatically label any relative as having decision-
making power, thus giving them the qualiﬁcation of a
‘legally authorised representative’, such a practice may be
ethically questionable. The provision of a legal framework
for recruiting incapacitated patients without decision-
makers is ethically sound since it allows for these patients to
potentially beneﬁt from experimental treatments. The lack
of a framework, on the other hand, effectively excludes
their participation, denying any possible beneﬁts.
Methodologically, it biases studies towards less severely ill
patients, thus denying current patients the potential bene-
ﬁts of new therapies and leading to uncertainty regarding
their costs and beneﬁts in similar patients in the future.
Finally, on a practical level, it makes it more difﬁcult for
researchers to conduct studies on the populations most in
need of new therapeutics, such as in our study. We claimed
that antibiotic treatment for severe infections such as bacter-
aemia and VAP caused by CR GNB fulﬁls all criteria for
emergency research. The FDA has a similar mechanism for
emergency research and we propose that future trials con-
ducted among patients with severe infections caused by CR
GNB be approved under this clause.
TRIAL STATUS
To date, 240 patients, or 67% of the planned total, have
been recruited within 25 months (of a planned 36),
including 178 in Israel, 40 in Greece and 22 in Italy. The
centre in Italy began participation more than a year
after the start of trial. An additional 204 patients (175 in
Israel, 27 in Greece and 2 in Italy) have been recruited
into the observational trial.
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